Phase 3 Trial Confirms Ibrance Plus Hormone Therapy Benefits ER+ Breast Cancer Patients

Phase 3 Trial Confirms Ibrance Plus Hormone Therapy Benefits ER+ Breast Cancer Patients
The CDK4/6 inhibitor Ibrance (palbociclib), when added to hormone therapy normally given to certain advanced breast cancer patients, considerably benefits these people, researchers at the University of California, Los Angeles (UCLA), reported in an article that detailed their findings in a Phase 3 clinical trial combining this breakthrough drug with Femara (letrozole). Specifically, trial results showed that Ibrance plus Femara significantly delayed cancer progression in postmenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, without the severe side effects associated with Femara monotherapy. The Phase 1 and Phase 2 trials that preceded this study were the basis for the U.S. Food and Drug Administration (FDA) approving Ibrance in combination with Femara for postmenopausal women with ER-positive, HER2-negative advanced breast cancer in February 2015, and for its European approval in that same indication earlier this month. The Phase 3 clinical trial and its study, "Palbociclib and Letrozole in Advanced Breast Cancer," published in The New England Journal of Medicine, seems to place Ibrance on a track for worldwide approval. Ibrance, developed by Pfizer, is designed to prevent cells from dividing by targeting a family of proteins, CDK4/6, that are critical for cell proliferation. The earlier, multi-year trials had shown that combining Ibrance with Femara led to a significant increase in progression-free survival compared to patients receiving Femara alone.
Subscribe or to access all post and page content.

4 comments

  1. Maureen Lopatynski says:

    Ibrance is so very expensive. Are there any trials for 72 year olds or are we just brushed under the carpet and forgotten as too old. We love living also.

    • Tim Bossie says:

      Unfortunately it may seem that way, but there are plenty of people who do not think that just because you are older you are to be forgotten. These trials do a lot of good for furthering research into treatments and meds. But, the costs can be quite substantial. Are you now undergoing treatment?

      • Maureen Lopatynski says:

        Starting next week. Have been trying for assistance. Waiting. Been taking faslodex for 10 months and it has failed me. Traveled the spine and hip. Lots of pain.

        • Maureen Lopatynski says:

          Had Breast cancer in 2005, had partial mastectomy, Chemo (FMS) and radiation. Nov.2015 had fluid in lung. after several invasive drainings I had to have surgery called VATS. Long recovery time for me (1 Month) in hospital and rehab. Faslodex for 10 months and now cancer in my bones, Hip and 3-4 vertebrae. Walking is painful. Now Femara and Ibrance. Ibrance outrageously expensive. Not sure I can afford it. Retail is $10,510.00. Any suggestions? Any open trial studies going on. I was in one back in 2005. Im usually strong, but beginning to feel helpless.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.